D. Boral Capital Reiterates Buy Rating for Trevi Therapeutics (NASDAQ:TRVI)

Trevi Therapeutics (NASDAQ:TRVI)‘s stock had its “buy” rating reiterated by D. Boral Capital in a research report issued on Thursday,Benzinga reports. They presently have a $21.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 403.60% from the company’s current price.

Several other equities analysts have also commented on TRVI. B. Riley restated a “buy” rating and issued a $6.00 price objective on shares of Trevi Therapeutics in a report on Monday, October 7th. EF Hutton Acquisition Co. I upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, August 19th. HC Wainwright reiterated a “buy” rating on shares of Trevi Therapeutics in a report on Wednesday, December 4th. Leerink Partnrs upgraded shares of Trevi Therapeutics to a “strong-buy” rating in a report on Monday, September 9th. Finally, Leerink Partners began coverage on shares of Trevi Therapeutics in a report on Monday, September 9th. They set an “outperform” rating and a $7.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Trevi Therapeutics currently has a consensus rating of “Buy” and an average price target of $9.31.

Trevi Therapeutics Stock Performance

Shares of TRVI stock opened at $4.17 on Thursday. The firm’s 50 day moving average price is $2.97 and its 200-day moving average price is $2.92. Trevi Therapeutics has a one year low of $1.22 and a one year high of $4.60. The firm has a market cap of $320.53 million, a P/E ratio of -9.48 and a beta of 0.96.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings data on Wednesday, November 6th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.01). During the same period in the previous year, the business posted ($0.08) EPS. As a group, research analysts predict that Trevi Therapeutics will post -0.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Trevi Therapeutics

A number of large investors have recently modified their holdings of the company. Barclays PLC increased its position in shares of Trevi Therapeutics by 180.8% in the 3rd quarter. Barclays PLC now owns 95,232 shares of the company’s stock valued at $319,000 after purchasing an additional 61,317 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Trevi Therapeutics by 10.2% in the 3rd quarter. Geode Capital Management LLC now owns 1,264,166 shares of the company’s stock valued at $4,223,000 after buying an additional 117,418 shares during the last quarter. State Street Corp grew its position in shares of Trevi Therapeutics by 5.9% in the 3rd quarter. State Street Corp now owns 952,912 shares of the company’s stock valued at $3,183,000 after buying an additional 53,051 shares during the last quarter. Fred Alger Management LLC purchased a new position in shares of Trevi Therapeutics in the 3rd quarter valued at $256,000. Finally, Acuta Capital Partners LLC grew its position in shares of Trevi Therapeutics by 11.7% in the 3rd quarter. Acuta Capital Partners LLC now owns 290,500 shares of the company’s stock valued at $970,000 after buying an additional 30,500 shares during the last quarter. 95.76% of the stock is owned by hedge funds and other institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.